THE SYNTHESIS AND EVALUATION OF NEW CARBOCYCLIC PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jongbok | - |
dc.contributor.author | Seo, Hyewon | - |
dc.contributor.author | Yoon, Sangeun | - |
dc.contributor.author | Choi, Kowoon | - |
dc.contributor.author | Lee, Chul-Hoon | - |
dc.contributor.author | Rhee, Hakjune | - |
dc.date.accessioned | 2021-06-22T23:03:26Z | - |
dc.date.available | 2021-06-22T23:03:26Z | - |
dc.date.issued | 2014-07 | - |
dc.identifier.issn | 0385-5414 | - |
dc.identifier.issn | 1881-0942 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/22396 | - |
dc.description.abstract | New carbocyclic pyrrolo[2,3-d]pyrimidine nucleoside analogs were synthesized with the key intermediate, 4-amino-6-bromo-5-cyanopyrrolo[2,3-c]pyrimidine (2), by S(N)2 reaction. One of the products, 4-amino-6-bromo-1-cyclopentyl-1H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (9), showed significant anti-proliferative activity to the human ovarian cancer PA-1 cells (IC50: 3.9 mu M). Based on the biological effects and the functional group characteristics of the compound 9, other carbocyclic nucleoside analogs related to the compound 9 were synthesized with key intermediate 2 by a Pd(0)-catalyzed coupling reaction. As expected, syn-4-amino-6-bromo-7[4-(methoxymethyl)-2-cyclopenten-1-yl]-17H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (15) showed very similar antiproliferative activity (IC50: 2.6 mu M) when compared to compound 9. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | THE SYNTHESIS AND EVALUATION OF NEW CARBOCYCLIC PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.3987/COM-14-12999 | - |
dc.identifier.scopusid | 2-s2.0-84903287118 | - |
dc.identifier.wosid | 000340335300004 | - |
dc.identifier.bibliographicCitation | Heterocycles, v.89, no.7, pp 1606 - 1619 | - |
dc.citation.title | Heterocycles | - |
dc.citation.volume | 89 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1606 | - |
dc.citation.endPage | 1619 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.subject.keywordPlus | PI-ALLYLPALLADIUM COMPLEXES | - |
dc.subject.keywordPlus | ANTIVIRAL AGENT CARBOVIR | - |
dc.subject.keywordPlus | EFFICIENT SYNTHESIS | - |
dc.subject.keywordPlus | HUMAN CYTOMEGALOVIRUS | - |
dc.subject.keywordPlus | TOYOCAMYCIN | - |
dc.subject.keywordPlus | SANGIVAMYCIN | - |
dc.subject.keywordPlus | TUBERCIDIN | - |
dc.subject.keywordPlus | CYTOTOXICITY | - |
dc.subject.keywordPlus | ANTIBIOTICS | - |
dc.subject.keywordPlus | PYRIMIDINES | - |
dc.subject.keywordAuthor | TOYOCAMYCIN | - |
dc.subject.keywordAuthor | ANTIBIOTICS | - |
dc.subject.keywordAuthor | ANTIVIRAL AGENT CARBOVIR | - |
dc.subject.keywordAuthor | HUMAN CYTOMEGALOVIRUS | - |
dc.subject.keywordAuthor | EFFICIENT SYNTHESIS | - |
dc.subject.keywordAuthor | TUBERCIDIN | - |
dc.subject.keywordAuthor | PYRIMIDINES | - |
dc.subject.keywordAuthor | SANGIVAMYCIN | - |
dc.subject.keywordAuthor | CYTOTOXICITY | - |
dc.subject.keywordAuthor | PI-ALLYLPALLADIUM COMPLEXES | - |
dc.identifier.url | https://www.researchgate.net/publication/273989490_The_Synthesis_and_Evaluation_of_New_Carbocyclic_Pyrrolo23-dpyrimidine_Nucleoside_Analogs | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.